Lexaria Bioscience Corp. Statistics
Share Statistics
Lexaria Bioscience Corp. has 17.45M shares outstanding. The number of shares has increased by 53.85% in one year.
| Shares Outstanding | 17.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 10.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 16.18M |
| Failed to Deliver (FTD) Shares | 10.57K |
| FTD / Avg. Volume | 7.56% |
Short Selling Information
The latest short interest is 277.08K, so 1.59% of the outstanding shares have been sold short.
| Short Interest | 277.08K |
| Short % of Shares Out | 1.59% |
| Short % of Float | 1.71% |
| Short Ratio (days to cover) | 2.62 |
Valuation Ratios
The PE ratio is -8.36 and the forward PE ratio is -5.9.
| PE Ratio | -8.36 |
| Forward PE | -5.9 |
| PS Ratio | 104.29 |
| Forward PS | 74.4 |
| PB Ratio | 6.03 |
| P/FCF Ratio | -9.76 |
| PEG Ratio | n/a |
Enterprise Valuation
Lexaria Bioscience Corp. has an Enterprise Value (EV) of 5.76M.
| EV / Earnings | -0.99 |
| EV / Sales | 12.4 |
| EV / EBITDA | -1 |
| EV / EBIT | -1 |
| EV / FCF | -1.16 |
Financial Position
The company has a current ratio of 7.18, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.18 |
| Quick Ratio | 7.18 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.68 |
| Cash Flow / Debt | -36.1 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.72% and return on capital (ROIC) is -73.79%.
| Return on Equity (ROE) | -0.72% |
| Return on Assets (ROA) | -0.65% |
| Return on Capital (ROIC) | -73.79% |
| Revenue Per Employee | 92.86K |
| Profits Per Employee | -1.16M |
| Employee Count | 5 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 76.38% in the last 52 weeks. The beta is 1.06, so Lexaria Bioscience Corp.'s price volatility has been higher than the market average.
| Beta | 1.06 |
| 52-Week Price Change | 76.38% |
| 50-Day Moving Average | 2.47 |
| 200-Day Moving Average | 3.03 |
| Relative Strength Index (RSI) | 45.56 |
| Average Volume (20 Days) | 139.84K |
Income Statement
In the last 12 months, Lexaria Bioscience Corp. had revenue of $464.28K and earned -$5.80M in profits. Earnings per share was $-0.47.
| Revenue | 464.28K |
| Gross Profit | 459.46K |
| Operating Income | -5.75M |
| Net Income | -5.80M |
| EBITDA | -5.75M |
| EBIT | -5.75M |
| Earnings Per Share (EPS) | -0.47 |
Balance Sheet
The company has $6.50M in cash and $137.37K in debt, giving a net cash position of $6.36M.
| Cash & Cash Equivalents | 6.50M |
| Total Debt | 137.37K |
| Net Cash | 6.36M |
| Retained Earnings | -51.56M |
| Total Assets | 8.87M |
| Working Capital | 6.80M |
Cash Flow
In the last 12 months, operating cash flow was -$4.96M and capital expenditures $0, giving a free cash flow of -$4.96M.
| Operating Cash Flow | -4.96M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.96M |
| FCF Per Share | -0.4 |
Margins
Gross margin is 98.96%, with operating and profit margins of -1.24K% and -1.25K%.
| Gross Margin | 98.96% |
| Operating Margin | -1.24K% |
| Pretax Margin | -1.25K% |
| Profit Margin | -1.25K% |
| EBITDA Margin | -1.24K% |
| EBIT Margin | -1.24K% |
| FCF Margin | -1.07K% |
Dividends & Yields
LEXX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -20.98% |
| FCF Yield | -12.69% |
Analyst Forecast
The average price target for LEXX is $11, which is 391.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 391.1% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 12, 2021. It was a backward split with a ratio of 1:30.
| Last Split Date | Jan 12, 2021 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | 10.27 |
| Piotroski F-Score | 3 |